- Home
- CHRS vs BEEP Comparison
CHRS vs BEEP Comparison
Compare CHRS & BEEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BEEP
- Stock Information
- Founded
- CHRS 2010
- BEEP 2015
- Country
- CHRS United States
- BEEP United States
- Employees
- CHRS 235
- BEEP N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BEEP Blank Checks
- Sector
- CHRS Health Care
- BEEP Finance
- Exchange
- CHRS Nasdaq
- BEEP Nasdaq
- Market Cap
- CHRS 134.4M
- BEEP 178.9M
- IPO Year
- CHRS 2014
- BEEP N/A
- Fundamental
- Price
- CHRS $1.22
- BEEP $3.93
- Analyst Decision
- CHRS Strong Buy
- BEEP
- Analyst Count
- CHRS 4
- BEEP 0
- Target Price
- CHRS $5.38
- BEEP N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- BEEP 44.2K
- Earning Date
- CHRS 03-12-2025
- BEEP 03-13-2025
- Dividend Yield
- CHRS N/A
- BEEP N/A
- EPS Growth
- CHRS N/A
- BEEP N/A
- EPS
- CHRS N/A
- BEEP N/A
- Revenue
- CHRS $304,340,000.00
- BEEP $35,743,000.00
- Revenue This Year
- CHRS $2.47
- BEEP N/A
- Revenue Next Year
- CHRS N/A
- BEEP $6.37
- P/E Ratio
- CHRS N/A
- BEEP N/A
- Revenue Growth
- CHRS 44.19
- BEEP 21.33
- 52 Week Low
- CHRS $0.66
- BEEP $2.48
- 52 Week High
- CHRS $2.87
- BEEP $4.86
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- BEEP 46.67
- Support Level
- CHRS $1.03
- BEEP $3.75
- Resistance Level
- CHRS $1.23
- BEEP $4.53
- Average True Range (ATR)
- CHRS 0.13
- BEEP 0.36
- MACD
- CHRS -0.02
- BEEP -0.02
- Stochastic Oscillator
- CHRS 38.89
- BEEP 38.03
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States. The company owns forty three parking facilities in twenty one separate markets throughout the United States, with a total of approximately fifteen thousand seven hundred parking spaces. The company derives majority of revenue from Percentage rental income.